Fresenius SE Stock News

Fresenius reported mediocre results and suspended the dividend this year, but management is optimistic for fiscal 2024. The company will focus on reducing debt levels in 2024 and the deconsolidation o

Fresenius reported a bigger-than-expected 13% jump in fourth-quarter operating profit on Wednesday, citing good earnings development across its businesses and progress in the operational turnaround at

Michael Sen, CEO at Fresenius, explains what the company is doing to help close the health care gap.

Fresenius SE & Co. KGaA (OTCPK:FSNUF) Q3 2023 Earnings Conference Call November 2, 2023 12:00 AM ET Company Participants Markus Georgi - Senior Vice President of Investor Relations Michael Sen - Chief

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest

Fresenius SE & Co. KGaA (OTCPK:FSNUF) Q2 2023 Earnings Conference Call August 2, 2023 7:30 AM ET Company Participants Markus Georgi - Senior Vice President of Investor Relations Michael Sen - Chief Ex

Fresenius, a German healthcare company, is highlighted as a promising investment due to its global presence, market leadership, and potential for significant growth in the coming years. Despite underp

The generic drug unit of Germany's Fresenius said on Monday the price for Idacio, its copycat version of Abbvie's top-selling rheumatoid arthritis drug, will be at a 5% discount to Humira's list price

Fresenius: Still Struggling, Still Undervalued.

Inflation and (expected) actions by the Federal Reserve continue to dominate market movements even though the turmoil in the financial sector shortly took center stage. Markets have started the new ye

Fresenius SE & Co. KGaA (OTCPK:FSNUF) Q4 2022 Results Conference Call February 22, 2023 7:30 AM ET Company Participants Markus Georgi - Senior Vice President-Investor Relations Michael Sen - Chief Exe

Over the last six months, Fresenius has seen the exit of its CEO, increasing activist exposure, and is reviewing the deconsolidation of its largest subsidiary Fresenius Medical Care. We view this deco

I've been buying Fresenius in small portions and adding to my position again and again over the past year. It's now more than 3% of my portfolio. While this company remains a long-term turnaround play

Fresenius SE is reporting mediocre results once again with Fresenius Medical Care struggling due to labor shortage and macroeconomic challenges. While Fresenius Medical Care and Fresenius Kabi are str

Fresenius SE & Co. KGaA (OTCPK:FSNUF) Q3 2022 Earnings Conference Call October 31, 2022 8:30 AM ET Company Participants Markus Georgi – Senior Vice President-Investor Relations Michael Sen – Chief